Driving Simulation to Assess Non-Sedative Effects of Tolperisone

Driving Simulation Cross-Over Study of Sedative Effects of Tolperisone Compared to Cyclobenzaprine and Placebo

This is a randomized blinded study to assess the sedative effect of 150 mg TID tolperisone and 10 mg TID cyclobenzaprine compared to placebo on simulated driving performance and cognitive functioning in healthy adult volunteers.

Study Overview

• Status: Completed
• Conditions: Driving Impaired
• Intervention / Treatment: Drug: Cyclobenzaprine 10 Mg Oral Tablet; Drug: Placebo Oral Tablet

Detailed Description

This will be a randomized, placebo-controlled, multiple-dose 3-way cross-over study of the safety and cognitive effects of multiple doses of 150 mg tolperisone administered TID in 30 male and female healthy volunteers. Treatment groups include 450 mg tolperisone (i.e., 150 mg administered three times daily), 30 mg cyclobenzaprine (i.e., 10 mg administered three times daily), and placebo. Subjects will receive 3 days of each treatment.

Subject participation will be approximately 3 weeks as outpatients with 3 days each week as overnight clinic participants.

In this crossover study, treatment effects will be assessed following the second initial dose, the morning following nighttime dosing (to assess residual next day effects), and at steady state (i.e., following AM dosing on Day 3).

Subjects will be dosed on the morning of Day 1. Approximately one hour after the second dose on Day 1, subjects will be administered the cognitive test, followed by the driving simulator examination.

On the morning of Day 2, prior to dosing, subjects will be readministered the cognitive test and driving examination to assess residual next day effects.

Subjects will repeat cognitive testing and the driving examination on the morning of Day 3, after administration of the AM study medication, to evaluate the cumulative effects of 3 days of dosing.

• Study Type: Interventional
• Enrollment (Actual): 35
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Long Beach, California, United States, 92845
      • Collaborative NeuroScience Network
  • Georgia
    • Atlanta, Georgia, United States, 30342
      • Neurotrials Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. All healthy volunteer subjects must be in general good health based on screening physical examination (defined as the absence of any clinically relevant abnormalities), medical history, 12-lead ECG, and clinical laboratory values (hematology, serum chemistry and urinalysis).
2. All subjects must be capable of understanding and complying with the protocol and have signed the informed consent document. Female subjects of childbearing potential must sign the Women of Childbearing Potential Addendum to the informed consent form.
3. Subjects are required to have a body mass index (BMI) of 18 to 32 kg/m2, inclusive, at Screening.
4. Subject must be able to reliably perform study assessments (i.e., SDLP no higher than 1 standard deviation greater than the mean for normal healthy adults completing the CVDA practice scenario; and number correct on CogScreen Symbol Digit Coding no less than 1 standard deviation below the mean for healthy adults in the 21-55 year age range); demonstrates the ability to understand task instructions (in English), and be physically capable (e.g., adequate manual dexterity, vision, and hearing), cognitively capable and motivated to perform study tasks.
5. Subject must possess a valid driver's license and be an active driver, and have driven a minimum of 10,000 miles (about 16,000 km) per year for the previous 3 years.
6. Subject must also demonstrate simulator sickness questionnaire scores which are not indicative of simulator sickness as defined in the driving simulation operations manual.
7. Subject must have a regular sleep pattern, not be engaged in shift-work, and in general, have at least 7 hours of sleep each night (bedtime occurs between 21:00 and 24:00 hours).
8. Subject has a score < 10 on the Epworth Sleepiness Scale (ESS).
9. Subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

1. Subjects who have any clinically significant unstable medical abnormality, chronic disease or a history of a clinically significant abnormality of the cardiovascular, gastrointestinal, respiratory, hepatic, or renal systems.
2. Subjects who test positive at screening for hepatitis B surface antigen, hepatitis C antibody or have a history of a positive result.
3. Subjects who are known to be seropositive or test positive at Screening for Human immunodeficiency virus (HIV).
4. Female subjects who are pregnant or lactating.
5. Subjects who have a disorder or history of a condition (e.g., malabsorption, gastrointestinal surgery) that may interfere with drug absorption, distribution, metabolism, or excretion.
6. A history within 2 years of, or current treatment for a sleeping disorder (including excessive snoring, obstructive sleep apnea), or a chronic painful condition that interferes with the subject's sleep.
7. A history of difficulty in falling asleep or staying asleep in the previous 3 months, that is considered clinically significant by the investigator.

8. Subjects who have a history or diagnosis of any of the following conditions:

   1. Primary or secondary insomnia
   2. Narcolepsy
   3. Cataplexy (familial or idiopathic)
   4. Circadian Rhythm Sleep Disorder
   5. Parasomnia including nightmare disorder, sleep terror disorder, sleepwalking disorder, and rapid eye movement behavior disorder
   6. Sleep-related Breathing Disorder (obstructive or central sleep apnea syndrome, central alveolar hypoventilation syndrome)
   7. Periodic Limb Movement Disorder
   8. Restless Legs Syndrome
   9. Primary Hypersomnia
   10. Excessive Daytime Sleepiness (EDS)
   11. Subject has visual or auditory impairment which in the opinion of the investigator would interfere with study related procedures or study conduct.
9. Subjects expected to use any other medication or dietary supplement to promote sleep including over-the-counter sleep medications, during their participation in the study.
10. Subjects who have participated in any investigational study within 30 days prior to screening or are currently participating in another clinical trial.
11. Subjects who have had a recent history (less than 2 years before entering the study) of drug or alcohol abuse, or current positive urine drug screen. Alcohol abuse is defined as current consumption of more than three alcoholic beverages per day.
12. Subjects who have a history of allergic reaction to tolperisone or cyclobenzaprine or any components of these study medications.
13. Use of psychoactive prescription or non-prescription medications, psychoactive nutritional supplements or herbal preparations within 2 weeks or 5 half-lives (whichever is longer) of admission to the Clinical Research Unit (CRU) on Day 1.
14. Presence of a medical or psychiatric condition which could jeopardize the safety of the subject or validity of study results
15. Subjects who consume excessive amounts of coffee, tea, cola, or other caffeinated beverages per day. Excessive amount is defined as greater than 6 servings per day (where 1 serving is approximately equivalent to 120 mg of caffeine).
16. Subjects who will be working a night shift within 1 week of a visit.
17. Subject who have traveled across 1 or more time zones (transmeridian travel) in the last 2 weeks prior to randomization or is expected to travel across 1 or more time zones during the study.
18. Current smoker (>10 cigarettes or eCigarettes, 3 cigars, or 3 pipes per day) and unwilling to refrain from smoking while confined to the CRU for periods of 3 days.
19. Subjects who have an inability or unwillingness to abide by the study protocol or cooperate fully with the Investigator or designee.
20. Subjects who are a staff member or relative of a staff member.
21. Inability or unwillingness to use adequate contraception (as defined in item 10 of the Inclusion Criteria) during and for 1 month following completion of the study.
22. Has a positive screen for alcohol or other drugs of abuse (amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tolperisone HCl 150 mg; 150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days	Drug: Cyclobenzaprine 10 Mg Oral Tablet; cyclobenzaprine 10 mg tablets; Other Names: Flexeril; Drug: Placebo Oral Tablet; sugar pill; Other Names: tolperisone matching placebo
Placebo Comparator: Placebo Oral Tablet; sugar pills administered by mouth every 8 hours for 3 days	Drug: Cyclobenzaprine 10 Mg Oral Tablet; cyclobenzaprine 10 mg tablets; Other Names: Flexeril; Drug: Placebo Oral Tablet; sugar pill; Other Names: tolperisone matching placebo
Active Comparator: Cyclobenzaprine 10 mg oral tablet; 10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days	Drug: Placebo Oral Tablet; sugar pill; Other Names: tolperisone matching placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Standard Deviation of Lateral Position (SDLP)	In this crossover study, treatment effects were assessed following initial dose, the morning following nighttime dosing (to assess residual next day effects), and at steady state (i.e., following AM dosing on Day 3).	at time of peak concentration of drug (Tmax) on Day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Standard Deviation of Lateral Position (SDLP) in Simulated Driving Test of Tolperisone Compared to Placebo on Day 2 Next Day Residual Effect	SDLP measured by simulated driving performance of tolperisone compared to placebo on Day 2 prior to morning dosing to determine the next day residual effect or hangover of treatment	in the morning predose on Day 2 following nighttime dosing
Sleepiness Endpoint Karolinska Sleepiness Scale KSS	assessment of self-reported motivation for driving performance where 1 equals alert and 9 equals extremely sleepy	at Tmax on Day 1
Steady State Standard Deviation of Lateral Position (SDLP) Day 3	SDLP measured on Day 3 at steady state following 3 days of dosing three times per day to achieve steady state drug concentration and effect on outcomes	Day 3

Collaborators and Investigators

• Sponsor: Neurana Pharmaceuticals, Inc.
• Collaborators: Cognitive Research Corporation

Study record dates

Study Major Dates

• Study Start (Actual): July 31, 2017
• Primary Completion (Actual): December 6, 2017
• Study Completion (Actual): January 30, 2018

Study Registration Dates

• First Submitted: November 14, 2017
• First Submitted That Met QC Criteria: November 21, 2017
• First Posted (Actual): November 27, 2017

Study Record Updates

• Last Update Posted (Actual): February 1, 2022
• Last Update Submitted That Met QC Criteria: January 28, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Keywords: cognitive function
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Tranquilizing Agents; Psychotropic Drugs; Antidepressive Agents; Antidepressive Agents, Tricyclic; Neuromuscular Agents; Muscle Relaxants, Central; Cyclobenzaprine; Tolperisone
• Other Study ID Numbers: NR115

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No